Welcome to our dedicated page for Atai Beckley news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on Atai Beckley stock.
AtaiBeckley Inc. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical and biotechnology company focused on developing effective, rapid-acting and convenient mental health treatments. The AtaiBeckley news feed on Stock Titan aggregates company announcements, press releases and regulatory disclosures so readers can follow how its clinical programs and corporate developments evolve over time.
News about AtaiBeckley frequently highlights progress across its pipeline of investigational therapies. This includes updates on BPL-003, a mebufotenin (5-MeO-DMT) benzoate nasal spray for treatment-resistant depression and alcohol use disorder; VLS-01, a DMT buccal film for treatment-resistant depression; and EMP-01, an oral R-MDMA formulation for social anxiety disorder. Company releases have covered Phase 2b and open-label extension data for BPL-003, enrollment and site expansion for VLS-01 trials, and exploratory Phase 2a work for EMP-01, as well as regulatory milestones such as FDA Breakthrough Therapy designation for BPL-003.
Investors and observers can also use the ATAI news page to follow corporate events, including the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited to form AtaiBeckley, the company’s redomiciliation to the United States as AtaiBeckley Inc., and its addition to the Nasdaq Biotechnology Index. Filings and press releases related to public offerings, grants from organizations such as the National Institute on Drug Abuse, and intellectual property developments like the U.S. patent granted for EMP-01 are also reflected in the news flow.
By reviewing AtaiBeckley news in one place, readers can track key clinical milestones, financing activities, regulatory designations and strategic transactions that shape the company’s efforts in mental health therapeutics. The ATAI news page can be revisited regularly to see new company communications and related market updates as they are released.
atai Life Sciences (Nasdaq: ATAI) announces a usability study of its Introspect Digital Therapeutics app, aimed at enhancing ketamine therapy for treatment-resistant depression (TRD), affecting 100 million globally. Conducted in collaboration with Kadima Neuropsychiatry, the study will assess user acceptability, therapeutic content introduction, and treatment settings across three cohorts. Atai believes this digital integration could improve access to mental health care, aligning with its mission to innovate psychiatric treatments and address the substantial unmet need in mental health.
atai Life Sciences (Nasdaq: ATAI) is set to participate in multiple investor conferences this September, focusing on mental health treatments.
Key events include:
- Citi 16th Annual BioPharma Conference on September 8, 2021, at 2:20 p.m. ET (Panel Discussion).
- H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 9:00 a.m. ET (Presentation).
- Baader Investment Conference on September 21, 2021, at 11:30 a.m. ET (Presentation).
- Cantor Fitzgerald Global Healthcare Conference on September 27, 2021, at 10:00 a.m. ET (Fireside Chat).
Archived webcasts will be available on the company's website.
atai Life Sciences (Nasdaq: ATAI) successfully completed its IPO, raising $258.8 million in gross proceeds. The company received $20 million from Otsuka for a collaborative effort in developing R-ketamine. It has advanced 11 therapeutic programs, with notable trials such as Recognify's Phase 2 and GABA's Phase 1 commencing. The company's cash position stands at $453.6 million, positioning it well for upcoming milestones, including 18 catalysts anticipated over the next 18 months.
atai Life Sciences (Nasdaq: ATAI) plans to host a conference call on August 16, 2021, at 8:30 a.m. ET to discuss its financial results for the second quarter ended June 30, 2021, and provide a business update.
The conference call can be accessed at 877-407-3982 in the U.S. and +1 (201) 493-6780 internationally, using conference ID: 13721888. A live and archived webcast will be available on the company's website.
atai Life Sciences N.V. (Nasdaq: ATAI) will participate in the virtual 41st Annual Canaccord Genuity Growth Conference from August 10-12, 2021. The company will conduct a fireside chat on August 10 at 2:30 p.m. ET. Interested parties can access the webcast here.
atai Life Sciences N.V. (Nasdaq: ATAI) announced its participation in the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on July 13, 2021. The company, focused on developing innovative therapies for mental health disorders, will present at 10:50 AM ET. Interested parties can access the presentation via a webcast link provided in the announcement. A replay will be available on atai's website. Founded in 2018, atai aims to transform mental health treatment through psychedelic and non-psychedelic compounds.
atai Life Sciences has priced its upsized initial public offering (IPO) at $15.00 per share, totaling 15,000,000 common shares and expected to raise $225.0 million. The offering is set to close on June 22, 2021, pending customary conditions. Additionally, underwriters have a 30-day option to purchase up to 2,250,000 shares at the offering price. Trading on the Nasdaq Global Market under the symbol ATAI begins on June 18, 2021. This IPO is crucial for atai's future endeavors in mental health treatment innovations.
atai Life Sciences announced an initial public offering (IPO) of 14,286,000 common shares, priced between $13.00 and $15.00 each. The underwriters have a 30-day option to purchase an additional 2,142,900 shares. The offering aims to enhance atai's capabilities in mental health treatments using innovative therapies. The shares are set to list on the Nasdaq under the ticker symbol ATAI, with Credit Suisse, Citigroup, and others acting as book-running managers. A registration statement has been filed but is not yet effective.